Latest News

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

Monitoring report documents HCV treatment access challenges across ADAP, Medicaid, and VA systems.

Patients face multiple monkeypox barriers: disorganized state websites, limited vaccine access, reporting gaps.

Provider language shows negative bias toward Black patients at 2.5x rate, undermining care engagement.

Only 35% of privately insured and 23% of Medicaid patients initiate HCV treatment due to payer barriers.

US monkeypox response: 31% of cases among Black persons, vaccine distribution equity concerns persist.

2020 CDC HIV surveillance reveals COVID-19's impact on HIV prevention and testing with decreased diagnoses and increased deaths.

STI and HCV rates rise despite reduced screening, reflecting chronic public health underfunding.

Global Fund report shows COVID-19 reduced HIV/HCV program efficacy while South Africa tripled ART coverage.

COVID-19 strains public health efforts addressing HIV outbreaks, diverting resources from the domestic epidemic.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.

Stagnant CMS reimbursement rates since 2016 threaten addiction treatment provider closures and service access.

COVID-19 disrupts STI surveillance as staff redeployment, testing shortages, and clinic closures create gaps.

Assesses pandemic's ongoing impact on HIV, HCV, and SUD surveillance and care with vaccine rollout.

Evaluates pandemic's impacts on HIV, HCV, and SUD services including testing disruptions and telehealth expansion.